Sudeep Pharma Q2FY27: Revenue surges 21% YoY to ₹196.7 Cr, EBITDA up 32%
Sudeep Pharma reported its highest-ever quarterly revenue of ₹196.7 crore (up 21% YoY) and EBITDA of ₹73.2 crore (up 32% YoY) for Q2 FY27. PAT increased 11% to ₹51.8 crore. The company received FDA approval for its Nandesari facility and expects commercial supplies in H2 FY27. The Dahej battery materials plant is on track for completion by March 2027.
The announcement details strong financial performance, achievement of significant operational milestones like FDA approval, and progress on strategic expansion projects in battery materials, all of which are material to the company's future growth and investor outlook.
The company reported record quarterly revenue and EBITDA with significant year-on-year growth. Key regulatory approvals and project milestones were achieved, indicating positive business momentum.
Sudeep Pharma Limited announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported its highest-ever quarterly revenue of ₹196.7 crore, marking a 21% year-on-year increase. EBITDA also reached a record high of ₹73.2 crore, a 32% increase YoY, with EBITDA margins improving to 37.2% from 34.1% in Q2 FY26. Profit After Tax (PAT) for the quarter stood at ₹51.8 crore, an 11% increase YoY.
The Pharma, Food & Nutrition (PFN) segment contributed 72% to the revenue, while Specialty Ingredients accounted for the remaining 28%. The company highlighted the continued traction of its AbsorBis product and progress in Magnesium Bisglycinate approvals.
Key developments during the quarter include the receipt of FDA approval for its Nandesari facility, with commercial supplies expected to commence in H2 FY27. The Dahej Phase 1 battery-grade iron phosphate facility (25,000 MTPA) is progressing as planned, with completion targeted by March 2027 and commercial operations from April 2027. The company is also evaluating an additional 1,00,000 MTPA capacity expansion for this facility.
For the half-year ended September 30, 2026 (H1 FY27), revenue grew by 23% YoY to ₹355.0 crore, and EBITDA increased by 29% YoY to ₹128.1 crore. PAT for H1 FY27 was ₹92.4 crore, an 18% increase YoY.
What to do with a filing like this
Sudeep Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudeep Pharma Limited. Read the original for the full detail.